代谢综合征痰证不同症候群病位、病性兼杂与脂蛋白酯酶基因多态性的关系研究  

Research on the relationship between the LPL gene polymorphism and the characteristic regularity of location, nature in different syndromes of metabolic syndrome with phlegm syndrome

作　　者：邵岩飞 张萍[2,3] 胡宇杰 邱雅婷 黄悦 王永发 康洁[2,5] 俞洁 李缘缘[2,3] 高碧珍 SHAO Yan-fei;ZHANG Ping;HU Yu-jie;QIU Ya-ting;HUANG Yue;WANG Yong-fa;KANG Jie;YU Jie;Li Yuan-yuan;GAO Bi-zhen(Ruijin Hospital,School of Medicine,Shanghai Jiaotong University,Shanghai 200025,China;Fujian University of Traditional Chinese Medicine,Fuzhou 350122,China;Key Laboratory of Chinese Medicine Health Status Differentiation of Fujian Province(Fujian University of Traditional Chinese Medicine),Fuzhou 350122,China;Jinjiang Hospital of Traditional Chinese Medicine Affiliated to Fujian University of Traditional Chinese Medicine,Jinjiang 362200,China;Collborative Innovation of Health Management of Traditional Chinese Medicine of Fujian Province in 2011,Fuzhou 350122,China)

机构地区：[1]上海交通大学医学院附属瑞金医院,上海200025 [2]福建中医药大学,福州350122 [3]福建省中医健康状态辨识重点实验室(福建中医药大学),福州350122 [4]福建中医药大学附属晋江中医院,福建晋江362200 [5]福建省2011中医健康管理协同创新中心,福州350122

出　　处：《中华中医药杂志》2022年第2期703-708,共6页China Journal of Traditional Chinese Medicine and Pharmacy

基　　金：国家自然科学基金项目(No.81873234,No.81273666);福建省自然科学基金面上项目(No.2018J01875);福建省2011中医健康管理协同创新中心资助项目(No.JG2017004-协同)。

摘　　要：目的:探讨代谢综合征(MS)痰证不同症候群病位、病性兼杂与脂蛋白酯酶(LPL)基因多态性位点rs10503669(A/C)的关系。方法:收集398例MS患者,180名健康人,采用证素辨证法将患者分为痰证(257例)和非痰证(141例),并根据2005年国际糖尿病联盟(IDF)诊断标准,将患者分为不同症候群组:中心性肥胖、高血压、糖代谢异常组(A组),中心性肥胖、高血压、血脂异常组(B组),中心性肥胖、血脂异常、糖代谢异常组(C组),中心性肥胖、高血压、血脂异常、糖代谢异常组(D组),采用多重SNP分型技术测定其LPL基因rs10503669位点的基因多态性,分析痰证和非痰证相应组间基因型频率、等位基因频率差异及其与痰证病位、病性兼杂的关系。结果:痰证A组LPL基因rs10503669位点风险基因型AA、CA及风险等位基因A的比例较健康组、非痰证A组显著升高(P<0.05,P<0.01),痰证A组病位证素肝、脾的AA、CA基因型频率远高于非肝、非脾(P<0.05)。结论:LPL基因rs10503669位点等位基因A是MS痰证人群中心性肥胖、高血压及糖代谢紊乱(A组)症候群的危险因素,其与MS痰证A组的形成有关,同时也可能与MS痰证A组症候群病位肝脾有关。Objective: To investigate the relationship of the LPL gene polymorphism site rs10503669(A/C) and the characteristic regularity of location, nature in different syndromes of metabolic syndrome with phlegm syndrome. Methods:A total of 398 patients with MS and 180 healthy people were collected. Then the patients were divided into phlegm syndrome(257 cases) and non-phlegm syndrome(141 cases) using the syndrome-element differentiation. According to the diagnostic criteria of International Diabetes Federation(IDF) in 2005, patients were divided into different syndrome groups: Central obesity, hypertension and abnormal glucose metabolism(group A);central obesity, hypertension and dyslipidemia(group B);central obesity, dyslipidemia,abnormal glucose metabolism(group C);central obesity, hypertension, dyslipidemia and abnormal glucose metabolism(group D).The multiplex SNP typing technique was used to detect the LPL gene polymorphism site rs10503669. Analyzing the differences in genotype frequency and allele frequency between the corresponding groups of phlegm syndrome and non-phlegm syndrome. Results:The proportion of risk genotypes AA, CA and risk allele A of LPL gene rs10503669 at phlegm syndrome group A was significantly higher than that of healthy group and non-phlegm group A(P<0.05, P<0.01). The disease locations liver and spleen of the phlegm syndrome group A had significantly higher AA and CA genotype frequencies than non-liver and non-spleen(P<0.05). Conclusion:The allele A of LPL gene polymorphism site rs10503669 is a risk factor for central obesity, hypertension and glucose metabolism disorder(group A) syndrome in MS phlegm syndrome patients, which is related to the formation of MS phlegm syndrome group A and may also be associated with the disease locations liver and spleen of MS phlegm syndrome group A.

关 键 词：代谢综合征 脂蛋白酯酶基因多态性 痰证 症候群 证素 

分 类 号：R259[医药卫生—中西医结合]